StockData
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Tango Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$23.53+1.49 (+6.76%)

Close on Oct 19, 2026

Market cap
$3.53B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026Before market open$0$-0.37–
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026After market close$0$-0.32–
Q4 FY2025
Ended Dec 31, 2025
Mar 5, 2026Before market open$0$-0.29–
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025Before market open$53.80M$0.13–
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025Before market open$3.18M$-0.35–
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025Before market open$5.40M$-0.36–
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025Before market open$4.10M$-0.35–
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024Before market open$11.61M$-0.27–
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024Before market open$19.88M$-0.24–
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Mar 18, 2024Before market open–––

Company guidance

Outlook given with results on Aug 5, 2025, compared with the previous outlook

MeasurePeriodGuidancevs. prior
revenuethe third quarter of 2025$53.80MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Tango Therapeutics filed with the SEC